IBM and Nvidia move quantum processors into supercomputing workflows
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
AI / NEWS BRIEF
OpenAI has acquired Orchestra Bio and plans to integrate its drug-development coordination platform and team into Rosalind. Financial terms were not disclosed.
OpenAI has acquired Orchestra Bio, a startup whose platform helps biopharmaceutical teams coordinate drug-development programs. OpenAI says it will combine Orchestra's employees and technology with Rosalind, its models and tools for life-sciences research. Axios independently reported the transaction and said its financial terms were not disclosed. Neither source states the purchase price, the size of Orchestra's team or a timetable for completing the integration.
Orchestra's software is designed to let scientists and program managers delegate operational work to AI agents, including monitoring studies, tracking timelines, identifying downstream effects of delays and comparing possible responses. OpenAI plans to use those capabilities alongside GPT-Rosalind and Rosalind Workbench, which focus on biological and chemical reasoning, scientific tools, data analysis and experiment planning. The stated aim is to connect scientific findings with the studies and decisions required to advance potential medicines.
The deal extends OpenAI beyond supplying general-purpose models into owning workflow software for a highly regulated industry. It also signals that competition among frontier laboratories is moving toward specialized scientific platforms and vertical integration. The acquisition does not demonstrate that Rosalind or Orchestra shortens clinical development, improves treatment outcomes or meets regulatory requirements; those effects will require evidence from deployed programs. No capability benchmark or REVAL score should change because of the transaction alone.
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
OpenAI has released healthcare-focused computer-use capabilities across its API and clinical products, with configurable approvals, audit logs and new performance results that remain provider-reported.